Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Cafestol reduces body weight and visceral fat but not insulin sensitivity
Last updated September 4, 2026
Key finding
Gamma-glutamyl transferase was significantly lowered after cafestol intake compared to placebo.
This study investigated the effects of purified cafestol on insulin sensitivity and metabolic parameters in healthy individuals with increased waist circumference, finding significant reductions in body weight and visceral fat volume.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of purified cafestol on insulin sensitivity and metabolic parameters in healthy individuals with increased waist circumference, finding significant reductions in body weight and visceral fat volume.
Clinical relevance
The findings suggest that cafestol could be a beneficial supplement for individuals looking to manage body weight and reduce visceral fat, which are important factors in metabolic health. Understanding its effects can help inform dietary recommendations and interventions aimed at reducing obesity-related health risks.
Keep in mind
The study had a limited sample size. Results may not be generalizable to populations outside the study group. Effectiveness of cafestol on insulin sensitivity remains unclear.
Published in
Journal Reference
Publication details and source links for this paper.
Fredrik DM, Mi DN, Kjeld H, et al. Effects of Purified Cafestol on Insulin Sensitivity and Metabolic Parameters in Healthy Individuals with Increased Waist Circumference. Nutrients. 2024;16(19):3232. doi:10.3390/nu16193232
Main Effects
Cafestol reduced gamma-glutamyl transferase by 15 U/L (p=0.019).
Cafestol led to a 2% reduction in body weight compared to placebo.
Cafestol resulted in a 5% decrease in visceral fat volume.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Cafestol and Body weight, Change in liver enzymes (GGT), Insulin Suppression Test Stage 1 SSPG, and 5 more.
This study contributes evidence to
Primary intervention
Cafestol
Primary outcomes
- Body weight
- Change in liver enzymes (GGT)
- Insulin Suppression Test Stage 1 SSPG
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
8
Evidence pairs
8
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
8
Evidence pairs
311
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 8 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Weight Loss
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Change in liver enzymes (GGT)
Cafestol → Change in liver enzymes (GGT)
Cafestol → Change in liver enzymes (GGT)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin Suppression Test Stage 1 SSPG
Cafestol → Insulin Suppression Test Stage 1 SSPG
Cafestol → Insulin Suppression Test Stage 1 SSPG
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin Suppression Test Stage 2 SSPG
Cafestol → Insulin Suppression Test Stage 2 SSPG
Cafestol → Insulin Suppression Test Stage 2 SSPG
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMixed Meal Test Glucose tAUC
Cafestol → Mixed Meal Test Glucose tAUC
Cafestol → Mixed Meal Test Glucose tAUC
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerMixed Meal Test Triglyceride tAUC
Cafestol → Mixed Meal Test Triglyceride tAUC
Cafestol → Mixed Meal Test Triglyceride tAUC
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPost-prandial insulin response after mixed-meal test
Cafestol → Post-prandial insulin response after mixed-meal test
Cafestol → Post-prandial insulin response after mixed-meal test
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Cafestol significantly lowered gamma-glutamyl transferase levels.
- Participants experienced a 2% reduction in body weight.
- Visceral fat volume decreased by 5% with cafestol intake.
Who this applies to
- Healthy adults with increased waist circumference.
- Individuals seeking to manage body weight and metabolic health.
Keep in Mind
- The study does not confirm the effectiveness of cafestol on insulin sensitivity.
- Findings are based on a specific population and may not apply broadly.
- Further research is needed to explore long-term effects and mechanisms.
Between the Lines
- The study had a limited sample size.
- Results may not be generalizable to populations outside the study group.
- Effectiveness of cafestol on insulin sensitivity remains unclear.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Cafestol and Body Weight, Cafestol and Insulin Suppression Test Stage 1 SSPG.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Cafestol → Body Weight
Supplements
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceSupplements
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Cafestol Evidence Hub
All studies on Cafestol
1 studies
intervention_hubContributes to Cafestol evidence base.
Insulin Suppression Test Stage 1 SSPG Evidence Hub
All studies measuring Insulin Suppression Test Stage 1 SSPG
1 studies
outcome_hubMeasures Insulin Suppression Test Stage 1 SSPG as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Cafestol and Body weight
Intervention: CafestolOutcome: Body weight
1 results
All studies on Cafestol and Insulin Suppression Test Stage 1 SSPG
Intervention: CafestolOutcome: Insulin Suppression Test Stage 1 SSPG
1 results
All studies on Cafestol
Intervention: Cafestol
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
All studies measuring Insulin Suppression Test Stage 1 SSPG
Outcome: Insulin Suppression Test Stage 1 SSPG
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Cafestol affect body weight?
Emerging Evidence
Cafestol appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Cafestol improve change in liver enzymes (GGT)?
Emerging Evidence
Cafestol appears to improve change in liver enzymes (GGT).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Change in liver enzymes (GGT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
What evidence is available on Cafestol and visceral fat reduction?
Emerging Evidence
Cafestol appears to reduce visceral fat reduction.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Visceral Fat Reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Cafestol improve insulin suppression test stage 1 sspg?
Emerging Evidence
Current evidence does not show a clear benefit of Cafestol for insulin suppression test stage 1 sspg.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Insulin Suppression Test Stage 1 SSPG
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Dietary interventions improve glycemic control in pre-diabetic patientsExercise Improves Serum Albumin Levels in Women with Type 2 DiabetesInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Metabolomics score improves metabolic profiling in diabetesPemvidutide improves liver fat and body weight in MASLD
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.